A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease is a phase 2 interventional study registered as NCT07023289 by AbbVie, with 140 participants planned, started 2025-09-02 and due to reach its primary completion in 2029-11. Interventions recorded: Telisotuzumab Adizutecan, Standard of Care. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.